Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.
Fitzel R, Secker-Grob KA, Keppeler H, Korkmaz F, Schairer R, Erkner E, Schneidawind D, Lengerke C, Hentrich T, Schulze-Hentrich JM, Schneidawind C. Fitzel R, et al. Among authors: korkmaz f. Neoplasia. 2023 Jul;41:100902. doi: 10.1016/j.neo.2023.100902. Epub 2023 May 4. Neoplasia. 2023. PMID: 37148657 Free PMC article.
The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.
Erkner E, Hentrich T, Schairer R, Fitzel R, Secker-Grob KA, Jeong J, Keppeler H, Korkmaz F, Schulze-Hentrich JM, Lengerke C, Schneidawind D, Schneidawind C. Erkner E, et al. Among authors: korkmaz f. Oncogene. 2024 Jan;43(4):281-293. doi: 10.1038/s41388-023-02903-3. Epub 2023 Nov 29. Oncogene. 2024. PMID: 38030791 Free PMC article.
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E, Secker KA, Nitulescu AM, Schairer R, Keppeler H, Wesle A, Schmid H, Schmitt A, Neuber B, Chmiest D, Podavini S, Märklin M, Klimovich B, Schmitt M, Korkmaz F, Lengerke C, Schneidawind C, Schneidawind D. Moraes Ribeiro E, et al. Among authors: korkmaz f. J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829. J Immunother Cancer. 2024. PMID: 38296597 Free PMC article.
Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype.
Schumacher M, Beer S, Moraes Ribeiro E, Korkmaz F, Keppeler H, Fitzel R, Erkner E, Radszuweit P, Lengerke C, Schneidawind C, Hoefert S, Mauz PS, Schneidawind D. Schumacher M, et al. Among authors: korkmaz f. Front Oncol. 2024 Mar 7;14:1333640. doi: 10.3389/fonc.2024.1333640. eCollection 2024. Front Oncol. 2024. PMID: 38515578 Free PMC article.